Finding Immune Nascent Type 1 Diabetes
FIND T1D
1 other identifier
interventional
3,800
1 country
1
Brief Summary
The goal of this clinical trial is to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication. The main question it aims to answer is: What form of recruitment communication is most effective for completing a type 1diabetes home screening kit? Researchers will compare two types of recruitment contact: email and mail based communication (low-touch) versus phone contact and follow-up by a research team member (high-touch). Participants will be contacted either via email/mail or by phone and asked if they want to complete a type 1 diabetes home screening kit.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2026
CompletedFirst Submitted
Initial submission to the registry
June 17, 2026
CompletedFirst Posted
Study publicly available on registry
June 23, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2029
June 23, 2026
June 1, 2026
3 years
June 17, 2026
June 17, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Rates of Returned Home Screening Kits
The number of returned screening kits versus the number that were not returned by consented participants.
From enrollment to the end of study at 3 years.
Rates of Consent
The number of participants who consent versus the number of participants who do not consent.
From enrollment to the end of study at 3 years.
Secondary Outcomes (1)
Percent of Kits with Adequate Blood Volume
From enrollment to the end of study at 3 years.
Study Arms (2)
Low-touch intervention
EXPERIMENTALHigh-touch intervention
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Participant must be in Indiana Biobank
- Participant must be able to provide consent
- Ages 1-99 including pregnant women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Indiana Universitylead
- Sanoficollaborator
Study Sites (1)
Indiana University School of Medicine
Indianapolis, Indiana, 46202, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor of Pediatrics
Study Record Dates
First Submitted
June 17, 2026
First Posted
June 23, 2026
Study Start
June 1, 2026
Primary Completion (Estimated)
June 1, 2029
Study Completion (Estimated)
June 1, 2029
Last Updated
June 23, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share
Participant results will be shared as summary data but because participants declining consent have not agreed we will not provide individual level data.